Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hellman, 1995, Oligometastases, J Clin Oncol Off J Am Soc Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8
Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003
Yoo, 2015, Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy, Radiat Oncol J, 33, 301, 10.3857/roj.2015.33.4.301
Conde Moreno, 2014, Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options, Radiat Oncol (London, England), 9, 258, 10.1186/s13014-014-0258-7
Tree, 2013, Stereotactic body radiotherapy for oligometastases, Lancet Oncol, 14, e28, 10.1016/S1470-2045(12)70510-7
Heidenreich, 2016, Role of salvage lymph node dissection in prostate cancer, Curr Opin Urol, 26, 581, 10.1097/MOU.0000000000000343
Wu, 2016, Radiotherapy combined with androgen deprivation for bone oligometastases after primary curative radiotherapy for prostate cancer: a retrospective study, Medicine, 95
Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs, PLoS One, 7, 10.1371/journal.pone.0050141
Lo, 2011, The role of local therapy in the management of lung and liver oligometastases, Nat Rev Clin Oncol, 8, 405, 10.1038/nrclinonc.2011.75
de Baere, 2017, The role of image-guided therapy in the management of colorectal cancer metastatic disease, Eur J Cancer (Oxford, England: 1990), 75, 231, 10.1016/j.ejca.2017.01.010
Yano, 2013, Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer, Lung Cancer (Amsterdam, Netherlands), 82, 431, 10.1016/j.lungcan.2013.08.006
Larbi, 2016, Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease, Prostate, 76, 1024, 10.1002/pros.23196
Lancia, 2017, Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis, Acta Oncol (Stockholm, Sweden), 1
Desai, 2017, Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer, Br J Radiol, 90, 20160500, 10.1259/bjr.20160500
Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022
Chybowski, 1991, Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters, J Urol, 145, 313, 10.1016/S0022-5347(17)38325-8
Cook, 2016, Imaging bone metastases in breast cancer: staging and response assessment, J Nucl Med Off Publ Soc Nucl Med, 57, 27s
Kyriazi, 2010, Imaging ovarian cancer and peritoneal metastases–current and emerging techniques, Nat Rev Clin Oncol, 7, 381, 10.1038/nrclinonc.2010.47
Lecouvet, 2016, Whole-body MR imaging: musculoskeletal applications, Radiology, 279, 345, 10.1148/radiol.2016142084
Lecouvet, 2012, Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?, Eur Urol, 62, 68, 10.1016/j.eururo.2012.02.020
Jouvet, 2014, Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study, J Eur Acad Dermatol Venereol JEADV, 28, 176, 10.1111/jdv.12078
Messiou, 2010, Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: a biomarker for treatment response monitoring, Cancer Biomark Sec A Dis Markers, 6, 21, 10.3233/CBM-2009-0116
Perez-Lopez, 2016, Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer, Radiology, 280, 151, 10.1148/radiol.2015150799
Blackledge, 2016, Inter- and intra-observer repeatability of quantitative whole-body, diffusion-weighted imaging (WBDWI) in metastatic bone disease, PLoS One, 11, e0153840, 10.1371/journal.pone.0153840
deSouza, 2017, Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives, Eur Radiol
Joice, 2017, Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology, Curr Opin Urol, 27, 533, 10.1097/MOU.0000000000000449
Van den Wyngaert, 2016, The EANM practice guidelines for bone scintigraphy, Eur J Nucl Med Mol Imaging, 43, 1723, 10.1007/s00259-016-3415-4
Boellaard, 2015, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur J Nucl Med Mol Imaging, 42, 328, 10.1007/s00259-014-2961-x
Fendler, 2017, 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, 44, 1014, 10.1007/s00259-017-3670-z
Fendler, 2017, 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study, J Nucl Med Off Publ Soc Nucl Med, 58, 1617
Fendler, 2017, 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients, J Nucl Med Off Publ Soc Nucl Med, 58, 307
Aide, 2017, EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies, Eur J Nucl Med Mol Imaging, 44, 17, 10.1007/s00259-017-3740-2
Novoa, 2016, Surgical management of oligometastatic non-small cell lung cancer, J Thorac Dis, 8, S895, 10.21037/jtd.2016.08.13
Corbin, 2013, Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy, J Clin Oncol Off J Am Soc Clin Oncol, 31, 1384, 10.1200/JCO.2012.45.9651
Madsen, 2016, Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer, Eur J Nucl Med Mol Imaging, 43, 2084, 10.1007/s00259-016-3407-4
Tonnies, 2016, Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer, Lung Cancer (Amsterdam, Netherlands), 93, 28, 10.1016/j.lungcan.2015.12.008
Tixier, 2016, Comparison of tumor uptake heterogeneity characterization between static and parametric 18F-FDG PET images in non-small cell lung cancer, J Nucl Med Off Publ Soc Nucl Med, 57, 1033
Casali, 2010, The variation of prognostic significance of maximum standardized uptake value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma, Lung Cancer (Amsterdam, Netherlands), 69, 187, 10.1016/j.lungcan.2009.10.015
Nakamura, 2015, Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography, Lung Cancer (Amsterdam, Netherlands), 87, 28, 10.1016/j.lungcan.2014.11.010
Reed, 2003, Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer, J Thorac Cardiovasc Surg, 126, 1943, 10.1016/j.jtcvs.2003.07.030
Erasmus, 2007, Positron emission tomography imaging in nonsmall-cell lung cancer, Cancer, 110, 2155, 10.1002/cncr.23051
Novello, 2016, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, 27, v1, 10.1093/annonc/mdw326
Sawada, 2016, Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography, Lung Cancer (Auckland, NZ), 7, 45
Ghaye, 2016, Imaging after radiation therapy of thoracic tumors, Diagn Interv Imaging, 97, 1037, 10.1016/j.diii.2016.06.019
Choi, 2011, Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer, Ann Thorac Surg, 92, 1826, 10.1016/j.athoracsur.2011.07.005
Ceci, 2017, New aspects of molecular imaging in prostate cancer, Methods (San Diego, Calif), 36, 10.1016/j.ymeth.2017.07.009
Evangelista, 2013, Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis, Eur Urol, 63, 1040, 10.1016/j.eururo.2012.09.039
Minamimoto, 2015, Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer, J Nucl Med Off Publ Soc Nucl Med, 56, 1862
Gupta, 2017, Comparative study of 68gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience, World J Nucl Med, 16, 186, 10.4103/1450-1147.207272
Obek, 2017, The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer, Eur J Nucl Med Mol Imaging, 44, 1806, 10.1007/s00259-017-3752-y
van Leeuwen, 2017, Prospective evaluation of 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer, BJU Int, 119, 209, 10.1111/bju.13540
Cantiello, 2017, Diagnostic accuracy of 64Copper prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience, Urology, 106, 139, 10.1016/j.urology.2017.04.019
Marzola, 2013, Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution, Clin Nucl Med, 38, e26, 10.1097/RLU.0b013e318266cc38
Evangelista, 2013, Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis, Clin Nucl Med, 38, 305, 10.1097/RLU.0b013e3182867f3c
Perera, 2016, Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021
Robertson, 2017, Combined whole body and multiparametric prostate magnetic resonance imaging as a 1-step approach to the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy, J Urol, 198, 65, 10.1016/j.juro.2017.02.071
Pasoglou, 2014, One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?, Prostate, 74, 469, 10.1002/pros.22764
Di Lascio, 2014, Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?, Breast Care (Basel, Switzerland), 9, 7, 10.1159/000358750
Martin, 2017, Brain metastases in newly diagnosed breast cancer: a population-based study, JAMA Oncol, 3, 1069, 10.1001/jamaoncol.2017.0001
Radan, 2006, The role of FDG-PET/CT in suspected recurrence of breast cancer, Cancer, 107, 2545, 10.1002/cncr.22292
Fueger, 2005, Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients, Mol Imag Biol MIB Off Publ Acad Mol Imaging, 7, 369, 10.1007/s11307-005-0013-4
Heusch, 2015, Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology, Eur J Nucl Med Mol Imaging, 42, 42, 10.1007/s00259-014-2885-5
Antoch, 2003, Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology, JAMA, 290, 3199, 10.1001/jama.290.24.3199
Heusner, 2010, Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging, Eur J Nucl Med Mol Imaging, 37, 1077, 10.1007/s00259-010-1399-z
Schmidt, 2008, Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT, Eur J Radiol, 65, 47, 10.1016/j.ejrad.2007.10.021
Melsaether, 2016, Comparison of whole-body (18)F FDG PET/MR imaging and whole-body (18)F FDG PET/CT in Terms of lesion detection and radiation dose in patients with breast cancer, Radiology, 281, 193, 10.1148/radiol.2016151155
Sawicki, 2016, Evaluation of (1)(8)F-FDG PET/MRI, (1)(8)F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer, Eur J Radiol, 85, 459, 10.1016/j.ejrad.2015.12.010
Ruers, 2009, Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study, J Nucl Med Off Publ Soc Nucl Med, 50, 1036
Moulton, 2014, Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial, JAMA, 311, 1863, 10.1001/jama.2014.3740
Franklin, 2016, Imaging oligometastatic cancer before local treatment, Lancet Oncol, 17, e406, 10.1016/S1470-2045(16)30277-7
Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol Off J Eur Soc Med Oncol, 27, 1386, 10.1093/annonc/mdw235
Maffione, 2015, Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review, Eur J Nucl Med Mol Imaging, 42, 152, 10.1007/s00259-014-2930-4
Niekel, 2010, Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment, Radiology, 257, 674, 10.1148/radiol.10100729
Wu, 2013, Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis, Eur J Cancer (Oxford, England : 1990), 49, 572, 10.1016/j.ejca.2012.08.021
Kim, 2015, Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques, Radiology, 274, 712, 10.1148/radiol.14140390
Zech, 2014, Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases, Br J Surg, 101, 613, 10.1002/bjs.9465
Zech, 2016, Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: results from the VALUE Trial, Eur Radiol, 26, 4121, 10.1007/s00330-016-4271-0
Spick, 2016, 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients, J Nucl Med Off Publ Soc Nucl Med, 57, 420
Goh, 2016, Positron emission tomography/magnetic resonance imaging of gastrointestinal cancers, Semin Ultrasound CT MRI, 37, 352, 10.1053/j.sult.2016.02.006
Van Beers, 2015, New imaging techniques for liver diseases, J Hepatol, 62, 690, 10.1016/j.jhep.2014.10.014
Ng, 2013, Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival, Radiology, 266, 177, 10.1148/radiol.12120254
Gillies, 2016, Radiomics: images are more than pictures, they are data, Radiology, 278, 563, 10.1148/radiol.2015151169
Nyflot, 2015, Quantitative radiomics: impact of stochastic effects on textural feature analysis implies the need for standards, J Med Imaging (Bellingham, Wash), 2
Larue, 2017, Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures, Br J Radiol, 90, 20160665, 10.1259/bjr.20160665
2017, Multidisciplinary quality assurance and control in oncological trials: perspectives from european organisation for research and treatment of cancer (EORTC), Eur J Cancer (Oxford, England: 1990), 86, 91, 10.1016/j.ejca.2017.07.039